Literature DB >> 27881005

A microRNA expression signature as a predictor of survival for colon adenocarcinoma.

M Xu, Y Kuang, M Wang, X Han, Q Yang.   

Abstract

Colon cancer is a major cause of cancer mortality worldwide and most colon cancers are adenocarcinoma. MicroRNA (miRNA) expression signature has been shown to be able to predict progression and prognosis of various cancers. The aim of our study was to explore a novel signature of microRNA expression for predicting survival of colon adenocarcinoma patients. By analyzing the miRNA expression profiles and clinical information of 329 colon adenocarcinoma patients derived from The Cancer Genome Atlas database. 129 miRNAs were identified to be expressed differentially between the cancer and adjacent tissues. Among them, 27 miRNAs were found to be associated with the corresponding clinical characteristics of the patients. Furthermore, 7 miRNAs (let-7a-2, mir-32, mir-181a-1, mir-197, mir-328, mir-505 and mir-652) were found to be significantly correlated with the patient survival. The risk established by the 7-miRNA signature we built was proved be an independent prognostic factor (Hazard ratio [HR] = 2.048; 95% CI = 1.144-3.664; p, 0.016). In summary, our study identified miRNAs correlated with progression and prognosis of colon adenocarcinoma and built a 7-microRNA expression signature for prediction of the survival of the patients with colon adenocarcinoma.

Entities:  

Keywords:  biomarker; colon cancer; microRNA survival.

Mesh:

Substances:

Year:  2017        PMID: 27881005     DOI: 10.4149/neo_2017_107

Source DB:  PubMed          Journal:  Neoplasma        ISSN: 0028-2685            Impact factor:   2.575


  12 in total

Review 1.  Targets and regulation of microRNA-652-3p in homoeostasis and disease.

Authors:  Maxwell T Stevens; Bernadette M Saunders
Journal:  J Mol Med (Berl)       Date:  2021-03-12       Impact factor: 4.599

Review 2.  microRNA-based diagnostic and therapeutic applications in cancer medicine.

Authors:  Lorenzo F Sempere; Asfar S Azmi; Anna Moore
Journal:  Wiley Interdiscip Rev RNA       Date:  2021-05-17       Impact factor: 9.957

3.  MicroRNA-505-5p functions as a tumor suppressor by targeting cyclin-dependent kinase 5 in cervical cancer.

Authors:  Elena Kapora; Shujun Feng; Wei Liu; Indira Sakhautdinova; Bo Gao; Wenhua Tan
Journal:  Biosci Rep       Date:  2019-07-25       Impact factor: 3.840

4.  miR‑505 suppresses prostate cancer progression by targeting NRCAM.

Authors:  Xiao-Hui Ling; Hao Fu; Zhi-Yun Chen; Jian-Ming Lu; Yang-Jia Zhuo; Jia-Hong Chen; Wei-De Zhong; Zhenyu Jia
Journal:  Oncol Rep       Date:  2019-07-11       Impact factor: 3.906

5.  Study on miRNAs in Pan-Cancer of the Digestive Tract Based on the Illumina HiSeq System Data Sequencing.

Authors:  Chun-Hui Lai; Xu-Zhi Liang; Xiu-Yun Liang; Sheng-Jun Ma; Jun-Guo Li; Ming-Fang Shi; Xu Zhu; Hui-Hua Lan; Jiang-Hui Zeng
Journal:  Biomed Res Int       Date:  2019-10-15       Impact factor: 3.411

Review 6.  The Metabolism Reprogramming of microRNA Let-7-Mediated Glycolysis Contributes to Autophagy and Tumor Progression.

Authors:  Chien-Hsiu Li; Chiao-Chun Liao
Journal:  Int J Mol Sci       Date:  2021-12-22       Impact factor: 5.923

7.  Protein-coding genes, long non-coding RNAs combined with microRNAs as a novel clinical multi-dimension transcriptome signature to predict prognosis in ovarian cancer.

Authors:  Xu Meng; Guo Jin-Cheng; Zhang Jue; Ma Quan-Fu; Yan Bin; Wu Xu-Feng
Journal:  Oncotarget       Date:  2017-08-24

8.  Prognostic value of microRNAs in colorectal cancer: a meta-analysis.

Authors:  Song Gao; Zhi-Ying Zhao; Rong Wu; Yue Zhang; Zhen-Yong Zhang
Journal:  Cancer Manag Res       Date:  2018-04-30       Impact factor: 3.989

9.  Downregulation of miR‑505‑3p predicts poor bone metastasis‑free survival in prostate cancer.

Authors:  Yubo Tang; Bowen Wu; Shuai Huang; Xinsheng Peng; Xing Li; Xiufang Huang; Wei Zhou; Peigen Xie; Peiheng He
Journal:  Oncol Rep       Date:  2018-10-25       Impact factor: 3.906

10.  Identifying a new microRNA signature as a prognostic biomarker in colon cancer.

Authors:  Yunxia Lv; Jinzhong Duanmu; Xiaorui Fu; Taiyuan Li; Qunguang Jiang
Journal:  PLoS One       Date:  2020-02-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.